Emerald Health Pharmaceuticals Receives IND Clearance to Begin Phase II Clinical Trial of EHP-101 for Relapsing Forms of Multiple Sclerosis

Emerald Health Pharmaceuticals, Inc. received clearance of its Investigational New Drug (IND) application by the FDA to begin enrolling patients in its Phase IIa clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (MS), specifically relapsing-remitting MS and active secondary progressive MS.
[Emerald Health Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (Nivolumab) for Treatment of Solid Tumors

BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy nivolumab.
[BioAtla, Inc. (PR Newswire, Inc.)]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase I/II Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.
[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase I Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide

Starton Therapeutics, Inc. announced that it has received its first Clinical Trial Authorization in the Netherlands to initiate a Phase I study evaluating STAR-LLD, a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia, bioavailability in human subjects.
[Starton Therapeutics, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio, Inc. announced the first patient has been dosed in the Phase III EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy.
[LianBio, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

NOXXON Provides Progress Update on the Expansion Arms of the Phase I/II GLORIA Trial with NOX-A12 in Brain Cancer Patients

NOXXON Pharma N.V. announced that the Data Safety Monitoring Board positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm.
[NOXXON Pharma N.V.]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase I Trial of AC0176 in Prostate Cancer

Accutar Biotechnology, Inc. announced that the US FDA has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic CRPC.
[Accutar Biotechnology, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Researchers Awarded Grant to Study New Method of Islet Transplantation

Weill Cornell Medicine researchers have received a two-year $500,000 grant from JDRF to evaluate an innovative approach to islet cell transplantation, an experimental treatment for difficult-to-control type 1 diabetes.
[Weill Cornell Medicine]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Longeveron Announces Initiation of Phase IIa Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

Longeveron, Inc. announced the initiation of its Phase IIa clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The Phase IIa trial is designed to measure brain anatomy using MRI, and include detailed assessments of the inflammatory and vascular systems thought to contribute to the worsening of AD.
[Longeveron, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Isolation of High Purity Mouse Mesenchymal Stem Cells through Depleting Macrophages Using Liposomal Clodronate

Researchers reported a novel strategy to generate highly pure mouse bone marrow MSCs using liposomal clodronate.
[Tissue Engineering and Regenerative Medicine]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

High Efficacy and Safety of CD38 and BCMA Bispecific CAR-T in Relapsed or Refractory Multiple Myeloma

The authors assessed the efficacy and safety of B cell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.
[Journal of Experimental & Clinical Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share